Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials
about
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patientsBiomarkers of treatment response in multiple sclerosisWhat went wrong? The flawed concept of cerebrospinal venous insufficiency.Intermediate uveitis: pattern of etiology, complications, treatment and outcome in a tertiary academic center.Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?Remyelination induced by a DNA aptamer in a mouse model of multiple sclerosis.Retinal nerve fibre layer thinning in patients with clinically isolated optic neuritis and early treatment with interferon-beta.Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional studyCo-delivery of autoantigen and b7 pathway modulators suppresses experimental autoimmune encephalomyelitis.Codelivery of antigen and an immune cell adhesion inhibitor is necessary for efficacy of soluble antigen arrays in experimental autoimmune encephalomyelitisImmune mediated diseases and immune modulation in the neurocritical care unitFrom injection therapies to natalizumab: views on the treatment of multiple sclerosis.Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis."Undiagnosing" multiple sclerosis: the challenge of misdiagnosis in MS.Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9-tetrahydrocannabinol in BV-2 microglial cells.Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?Practice patterns of US neurologists in patients with SPMS and PPMS: A consensus studyPractice patterns of US neurologists in patients with CIS, RRMS, or RIS: A consensus studyTherapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis.Natural history of multiple sclerosis symptomsCurrent understanding on the role of standard and immunoproteasomes in inflammatory/immunological pathways of multiple sclerosis.Ion channels in autoimmune neurodegeneration.Rehabilitation interventions in multiple sclerosis: an overview.Misdiagnosis of multiple sclerosis: frequency, causes, effects, and prevention.An update on the use of cerebrospinal fluid analysis as a diagnostic tool in multiple sclerosis.The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study(1)H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis.[Interferon-β1b in multiple sclerosis therapy: more than 20 years clinical experience].White matter and deep gray matter hemodynamic changes in multiple sclerosis patients with clinically isolated syndrome.The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.Cladribine in multiple sclerosis: pitfalls in a new treatment landscape.Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis.Orthologous proteins of experimental de- and remyelination are differentially regulated in the CSF proteome of multiple sclerosis subtypes
P2860
Q21093230-61669025-A559-4C9D-98A3-3BA5B11E48B4Q28305094-96E4C535-79BD-4737-A227-20608946A58FQ30454634-F29C3629-612E-4F2B-B595-1747B79E8983Q33612642-AC8BCFD1-85D9-427D-B802-4F79BE49E6B6Q34204413-EB52233C-0FEA-4DDB-95FD-7635CAAFCBF7Q34326301-06297EB4-49E7-4404-A06F-A927FA4A393BQ34525419-9A430FFA-12DF-4E68-9214-17532865968EQ34926430-5C3496ED-3E96-43BC-AADA-87EB3D7AE6C1Q35318380-9DF36004-FD0C-4160-9BCD-33C746839CABQ35571156-B5433ABB-F45C-4FC9-9366-352F82B980D6Q35729575-4D4859F6-41E0-4C19-8BE5-284C581BF8DAQ35825914-3C8F76B0-2FFC-4D10-AE55-6A46F503E7C9Q35853209-6F326AC8-DCD4-483B-B825-BA04AD9D81BCQ36014657-B2BA9A88-36F4-4449-B783-1B5A06E14C4BQ36176444-09119357-AE13-434C-AB0D-2B72FE04524CQ36648907-0FCD6386-1425-43B7-99CE-E4EE3C3EEFE9Q36731484-4EBC3299-6E71-4257-8DE5-8835F6F94ED3Q36731490-1E30A47E-6C3D-426B-A150-3FA74DB25067Q37403700-DBF8438A-FDD9-4845-8E2F-6DCDA3E3F8BCQ37442391-255C7394-B714-44FE-82C2-4CFCC6104E46Q37541906-3B040B5B-2917-434C-B1D3-D519D10AF871Q37866428-781E8A5E-DEE9-405A-B117-673EC4BF01ABQ38024650-1FDB9006-AF73-437C-AFD7-02CC9BB64B2AQ38154241-B05AD905-D4C1-4FEC-A81E-467ADF473C00Q39027028-4DBD5A4E-3C44-4837-9DBA-C2509C1C8536Q39434905-A0F5D876-79CE-45E1-93F0-1354D6BC2EACQ40133625-978E5D36-2BDD-4B12-B88D-09BBE14D3AEAQ45155454-D2A79305-A881-4F6F-8D2A-04D5C9572B61Q45324992-55B5EA4B-37C1-4EC5-9CC7-A260E322A1A7Q45961588-921FC75B-48E1-4CB0-8DE8-E9B07BDFA5CFQ46403566-EAC665E7-EFD8-41C2-957E-C2A0C9C05E9FQ48256822-AD0CCCE7-B7D3-440E-B321-DD3DCC58A42AQ58774884-986D153F-AC23-4DBE-9B80-8345CF19461D
P2860
Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Treatment effects of immunomod ...... sclerosis in short-term trials
@ast
Treatment effects of immunomod ...... sclerosis in short-term trials
@en
Treatment effects of immunomod ...... sclerosis in short-term trials
@en-gb
Treatment effects of immunomod ...... sclerosis in short-term trials
@nl
type
label
Treatment effects of immunomod ...... sclerosis in short-term trials
@ast
Treatment effects of immunomod ...... sclerosis in short-term trials
@en
Treatment effects of immunomod ...... sclerosis in short-term trials
@en-gb
Treatment effects of immunomod ...... sclerosis in short-term trials
@nl
prefLabel
Treatment effects of immunomod ...... sclerosis in short-term trials
@ast
Treatment effects of immunomod ...... sclerosis in short-term trials
@en
Treatment effects of immunomod ...... sclerosis in short-term trials
@en-gb
Treatment effects of immunomod ...... sclerosis in short-term trials
@nl
P1433
P1476
Treatment effects of immunomod ...... sclerosis in short-term trials
@en
P2093
P304
P356
10.1212/WNL.0B013E3182050388
P407
P433
1, Supplement 1
P577
2010-12-27T00:00:00Z